Director, Chief Physician, Professor, Doctoral Supervisor, Doctor of Medicine, Department of Breast Oncology, Peking University Cancer Hospital; Vice Chairperson and Secretary-General of the Clinical Oncology Expert Committee of the Chinese Women Doctors Association; Director of the Cancer Patient Education Center of the Chinese Women Doctors Association. Executive Member of the Chinese Society of Clinical Oncology (CSCO) of the Chinese Anti-Cancer Association; Member of the Expert Panel for the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Chinese Edition); Editorial Board Member of the *Journal of Cancer Progress*; Youth Committee Member of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association; Evaluation Expert for Key Projects of the Ministry of Science and Technology; Evaluation Expert for the National Natural Science Foundation of China; New Drug Evaluation Expert for the National Medical Products Administration. In 1993, participated in a molecular biology techniques training course organized by the International Atomic Energy Agency in Japan. From June 2001 to June 2003, served as a visiting scholar at the University of Texas M.D. Anderson Cancer Center in the United States for two years. As project leader, received: 1997 Hospital Youth Fund, 2003 Returned Personnel Startup Fund, two National Natural Science Foundation of China grants, one Wu Jieping Medical Foundation grant, and two Estée Lauder Group grants. Main research direction: Comprehensive treatment strategies for breast cancer. Has delivered over 200 lectures on breast cancer treatment progress across China and served as an English interpreter at international conferences more than 60 times. Participated in multiple lighting ceremonies for the "Pink Ribbon Breast Cancer Prevention and Control Campaign." Primary clinical and research areas: Diagnosis and treatment of recurrent, metastatic, and de novo stage IV breast cancer, with a focus on chemotherapy, endocrine therapy, targeted therapy, and immunotherapy for breast cancer. Led multiple clinical studies on BRCA-mutant breast cancer, resulting in the market approval of precision targeted therapies in this field, which have been included in guidelines and approved for medical insurance reimbursement. Also served as co-chair in publishing the "Chinese Consensus Guidelines for Advanced Breast Cancer" and has conducted research on breast cancer risk factor investigations, standardized collection of basic breast cancer data, and AI-empowered integration. Two years of study at the University of Texas M.D. Anderson Cancer Center. Chairperson of the Breast Professional Committee of the Chinese Women Doctors Association; Deputy Head of the Breast Oncology Group of the Oncology Branch of the Chinese Medical Association; Standing Committee Member of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association; Vice Chairperson of the Clinical Oncology Committee of the Chinese Women Doctors Association; Co-Chair and Lead Author of the Chinese Consensus Guidelines for Advanced Breast Cancer; Associate Editor of *Breast Cancer Research and Treatment*.